| URL | https://www.contractpharma.com/contents/view_break |
| Source | contractpharma.com |
| Date Published | 04/05/2023 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Sanofi |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2023 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | France |
| City reshored to: | Swiftwater |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | recombinant pandemic influenza vaccines |
| What domestic positive factors made reshoring more attractive? | Government Incentives, BARDA contract |